Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28872527 | 0.78 | PRSS1 (0.31) | TDP1 | |
| SCHEMBL213629 | 0.76 | — | — | |
| SCHEMBL9403546 | 0.75 | DGAT1 (0.43) | DGAT1TDP1CTSK | |
| SCHEMBL31729965 | 0.75 | DGAT1 (0.43) | DGAT1TDP1CTSK | |
| SCHEMBL28872530 | 0.72 | ALDH1A1 (0.43) | TDP1 | |
| SCHEMBL28714306 | 0.72 | DGAT1 (0.40) | DGAT1CTSK | |
| SCHEMBL307610 | 0.71 | DGAT1 (0.55) | DGAT1TDP1 | |
| SCHEMBL3141601 | 0.71 | DGAT1 (0.79) | DGAT1TDP1 | |
| SCHEMBL3620330 | 0.70 | DGAT1 (0.39) | DGAT1CTSK | |
| SCHEMBL23336295 | 0.70 | TDP1 (0.48) | DGAT1TDP1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230083012-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2023-03-16 | — | — | US | disclosed |
| US-20230002408-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2023-01-05 | — | — | US | disclosed |
| EP-4077305-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Janssen Pharmaceutica NV (BE) | 2022-10-26 | — | — | EP | disclosed |
| US-11427598-B2 | Spiro-cyclic amine derivatives as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2022-08-30 | — | — | US | disclosed |
| CN-114867717-A | Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection | 詹森药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-4003355-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-01 | — | — | EP | disclosed |
| CN-114173787-A | Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases | 杨森科学爱尔兰无限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20210130364-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2021-05-06 | — | — | US | disclosed |
| US-10807991-B2 | Spiro-cyclic amine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2020-10-20 | — | — | US | disclosed |
| CN-107207514-B | Fused heteroaryl compounds and their use as TRK inhibitors | 康联制药有限公司 | 2020-01-24 | — | — | CN | disclosed |
| EP-3144312-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | AbbVie B.V. (NL) | 2017-03-22 | — | — | EP | disclosed |
| EP-2590955-B9 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2017-02-22 | — | — | EP | disclosed |
| US-20160340363-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-11-24 | — | — | US | disclosed |
| EP-2590955-B1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2016-10-12 | — | — | EP | disclosed |
| CN-103097364-B | Spiro-piperidine derivatives as S1P modulators | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2015-11-25 | — | — | CN | disclosed |
| US-20130196998-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-01 | — | — | US | disclosed |
| EP-2590955-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-05-15 | — | — | EP | disclosed |
| CN-103097364-A | Spiro-piperidine derivatives as S1P modulators | ABBOTT HEALTHCARE PRODUCTS BV | 2013-05-08 | — | — | CN | disclosed |
| WO-2012004378-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | PALATIN TECHNOLOGIES, INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427598-B2 | Spiro-cyclic amine derivatives as S1P modulators | S1PR1, S1PR3, S1PR2 | DGAT1 1720/4885TDP1 3197/4885CTSK 4151/4885 |
| US-20130196998-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | DGAT1 1290/4885TDP1 2741/4885CTSK 4525/4885 |
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | ARGLU1, QRFPR, ARG1 | DGAT1 4730/4885TDP1 3303/4885CTSK 1454/4885 |
| US-10807991-B2 | Spiro-cyclic amine derivatives as S1P modulators | S1PR1, S1PR3, S1PR2 | DGAT1 1720/4885TDP1 3197/4885CTSK 4151/4885 |
| US-20160340363-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | DGAT1 1613/4885TDP1 3031/4885CTSK 4161/4885 |
| US-20230083012-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | DGAT1 3188/4885TDP1 1612/4885CTSK 3726/4885 |
| US-20210130364-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | DGAT1 1720/4885TDP1 3197/4885CTSK 4151/4885 |
| US-20230002408-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | DGAT1 2313/4885TDP1 1909/4885CTSK 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.